Jeffrey Frankel

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder

Sender Herschorn, Jack Barkin, David Castro‐Díaz et al. · Urology · 2013 · 246 citations

Medicine, Pharmacology, Pharmacotherapy +13

The Prognostic Significance of Post-Irradiation Biopsy Results in Patients with Prostatic Cancer

Peter T. Scardino, Jeffrey Frankel, Thomas M. Wheeler et al. · The Journal of Urology · 1986 · 146 citations

Medicine, Oncology, Radiation Oncology +15

International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR

David Staskin, Jeffrey Frankel, Susann Varano et al. · The Journal of Urology · 2020 · 120 citations

Medicine, Pharmacology, Pharmacotherapy +16

Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR)

David Staskin, Jeffrey Frankel, Susann Varano et al. · The Journal of Urology · 2020 · 43 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study

Susann Varano, David Staskin, Jeffrey Frankel et al. · Drugs & Aging · 2021 · 29 citations · Full text

Medicine, Pharmacotherapy, Urology +17